<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5984627</article-id><article-id pub-id-type="publisher-id">4530</article-id><article-id pub-id-type="doi">10.1038/s41467-018-04530-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Recurrent rearrangements of <italic>FOS</italic> and <italic>FOSB</italic> define osteoblastoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5172-4100</contrib-id><name><surname>Fittall</surname><given-names>Matthew W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mifsud</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0579-4105</contrib-id><name><surname>Pillay</surname><given-names>Nischalan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Hongtao</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Strobl</surname><given-names>Anna-Christina</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Verfaillie</surname><given-names>Annelien</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2660-2478</contrib-id><name><surname>Demeulemeester</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Berisha</surname><given-names>Fitim</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tarabichi</surname><given-names>Maxime</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Matthew D.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tarpey</surname><given-names>Patrick S.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tirabosco</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Amary</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Grigoriadis</surname><given-names>Agamemnon E.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Stratton</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0292-1949</contrib-id><name><surname>Van Loo</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Antonescu</surname><given-names>Cristina R.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Campbell</surname><given-names>Peter J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Flanagan</surname><given-names>Adrienne M.</given-names></name><address><email>a.flanagan@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Behjati</surname><given-names>Sam</given-names></name><address><email>sb31@sanger.ac.uk</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1795 1830</institution-id><institution-id institution-id-type="GRID">grid.451388.3</institution-id><institution>The Francis Crick Institute, </institution></institution-wrap>London, NW1 1AT UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>University College London Cancer Institute, </institution></institution-wrap>London, WC1E 6DD UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0606 5382</institution-id><institution-id institution-id-type="GRID">grid.10306.34</institution-id><institution>Wellcome Trust Sanger Institute, </institution></institution-wrap>Hinxton, Cambridgeshire CB10 1SA UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 5902 9895</institution-id><institution-id institution-id-type="GRID">grid.424537.3</institution-id><institution>Great Ormond Street Hospital for Children NHS Foundation Trust, </institution></institution-wrap>London, WC1N 3JH UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0467 5857</institution-id><institution-id institution-id-type="GRID">grid.412945.f</institution-id><institution>Department of Histopathology, </institution><institution>Royal National Orthopaedic Hospital NHS Trust, </institution></institution-wrap>Stanmore, Middlesex HA7 4LP UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0668 7884</institution-id><institution-id institution-id-type="GRID">grid.5596.f</institution-id><institution>Department of Human Genetics, </institution><institution>University of Leuven, </institution></institution-wrap>Leuven, 3000 Belgium </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution>Department of Pathology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY 10065 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.239826.4</institution-id><institution>Centre for Craniofacial and Regenerative Biology, King&#8217;s College London, </institution><institution>Guy&#8217;s Hospital, </institution></institution-wrap>London, SE1 9RT UK </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Department of Paediatrics, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, CB2 0QQ UK </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2150</elocation-id><history><date date-type="received"><day>23</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>8</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The transcription factor <italic>FOS</italic> has long been implicated in the pathogenesis of bone tumours, following the discovery that the viral homologue, <italic>v-fos</italic>, caused osteosarcoma in laboratory mice. However, mutations of <italic>FOS</italic> have not been found in human bone-forming tumours. Here, we report recurrent rearrangement of <italic>FOS</italic> and its paralogue, <italic>FOSB</italic>, in the most common benign tumours of bone, osteoblastoma and osteoid osteoma. Combining whole-genome DNA and RNA sequences, we find rearrangement of <italic>FOS</italic> in five tumours and of <italic>FOSB</italic> in one tumour. Extending our findings into a cohort of 55 cases, using FISH and immunohistochemistry, provide evidence of ubiquitous mutation of <italic>FOS</italic> or <italic>FOSB</italic> in osteoblastoma and osteoid osteoma. Overall, our findings reveal a human bone tumour defined by mutations of <italic>FOS</italic> and <italic>FOSB</italic>.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2"><italic>FOS</italic> has been linked to bone tumour pathogenesis, and viral homologue <italic>v-fos</italic> causes osteosarcoma in mice. Here, the authors report rearrangement of <italic>FOS</italic> and its paralogue <italic>FOSB</italic> in osteoblastoma and osteoid osteoma, revealing human bone tumours that are defined by mutations of <italic>FOS</italic> and <italic>FOSB</italic>.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Osteoblastoma is the most common benign bone-forming tumour. It typically occurs in the medulla of long bones and the neural arch from where it may extend into the vertebral body<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Osteoid osteoma is thought to represent a variant of osteoblastoma. The two entities are distinguished arbitrarily by size, with osteoblastoma measuring more than 2&#8201;cm in diameter. Large, inaccessible and recurrent tumours can cause considerable morbidity<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Treatment is by surgical resection. The genetic changes underpinning osteoblastoma have been studied at the resolution of karyotypes and copy number arrays. Copy number losses involving chromosome 22 and rearrangements involving chromosome 14 have been reported in rare cases only<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par4">Diagnosis of osteoblastoma is currently based on histological assessment. Occasionally this can be challenging, as osteoblastoma has to be distinguished from osteoblastic osteosarcoma, an aggressive bone cancer that requires extensive, sometimes disabling, multimodal treatment<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par5">Here, we sought to define the somatic changes that underpin osteoblastoma. Our starting point was a discovery cohort of six tumours, five osteoblastomas and one osteoid osteoma, that we subjected to RNA and whole-genome DNA sequencing. Tissue was obtained from frozen tumour and corresponding germline DNA sequences derived from blood samples. Using the analysis pipeline of the Cancer Genome Project (&#8216;Methods&#8217;), we generated catalogues of all classes of somatic mutations: substitutions, indels, structural variants (rearrangements) and copy number changes. Transcriptome sequences were analysed to corroborate DNA changes and to call gene fusions.</p><p id="Par6">Our key finding was recurrent, disease-defining structural variation of the <italic>FOS</italic> and <italic>FOSB</italic> oncogenes in osteoblastoma and osteoid osteoma.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Osteoblastoma habours few somatic alterations</title><p id="Par7">Overall, there was a paucity of somatic alterations in osteoblastoma, with a median mutation burden of 319 substitutions per genome (range, 123&#8211;700) and 28 indels per genome (range, 14&#8211;50; Supplementary Data&#160;<xref rid="MOESM4" ref-type="media">1</xref>&#8211;<xref rid="MOESM6" ref-type="media">3</xref>). Similarly, copy number analyses demonstrated diploid tumours with few aberrations (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref> and Supplementary Data&#160;<xref rid="MOESM7" ref-type="media">4</xref>). The previously reported losses in chromosome 22 were not seen in our cases<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Only a small number of mutations affected the coding sequence of genes, none of which were plausible driver events.</p></sec><sec id="Sec4"><title>Recurrent <italic>FOS</italic> and <italic>FOSB</italic> rearrangements</title><p id="Par8">Against this backdrop of a quiet somatic architecture, analysis of structural variants revealed break points in the AP-1 transcription factor <italic>FOS</italic>, in 5/6 cases, and its paralogue <italic>FOSB</italic> in the sixth case (Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>; and Supplementary Data&#160;<xref rid="MOESM8" ref-type="media">5</xref>). We analysed and validated these rearrangements at the DNA level by local assembly, copy number analyses and at the RNA level by identification of break point spanning cDNA reads (Supplementary Data&#160;<xref rid="MOESM9" ref-type="media">6</xref>&#8211;<xref rid="MOESM11" ref-type="media">8</xref>). A single <italic>FOS</italic> or <italic>FOSB</italic> break point was confirmed in each sample, suggesting that these were mono-allelic rearrangements. There was no evidence of similar rearrangements in paired normal tissue samples, confirming that they were somatic. <italic>FOS</italic> rearrangements were also validated with Sanger sequencing of cDNA (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p><italic>FOS</italic> fusions in osteoblastoma. <bold>a</bold> Clustered break points in <italic>FOS</italic>. <bold>b</bold> Central Circos plot showing the clustering of break points in <italic>FOS</italic>-mutant samples. All structural variants involving chromosome 14 are shown, demonstrating the paucity of genomic rearrangements. Surrounding panels demonstrate normalised RNA-Seq read counts for each fusion partner. Horizontal line segments reflect mean sequencing counts. The arrow above shows the direction of transcription of the fusion. <bold>c</bold> Retroviral <italic>v-fos</italic>. <bold>d</bold> Schematic of <italic>FOS</italic> break points in benign bone and vascular tumours generating similarity with the murine retroviral transforming <italic>v-fos</italic>. Subscript numbers from left to right report the length of the transcript to the stop codon and the predicted cleavage and poly-adenylation site, respectively. <bold>e</bold> FOS immunohistochemistry demonstrating strong nuclear immunoreactivity in <italic>FOS</italic>-mutant osteoblastoma, PD13482 (centre with zoom inset), Haematoxylin and eosin (H&amp;E) (left), and a clear breakapart of FISH probes surrounding the <italic>FOS</italic> locus (right)</p></caption><graphic xlink:href="41467_2018_4530_Fig1_HTML" id="d29e677"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p><italic>FOSB</italic> fusion in PD7525. <bold>a</bold> Schematic of the <italic>PPP1R10-FOSB</italic> fusion. The <italic>PPP1R10</italic> exon 16 splice donor site is skipped, resulting in exonisation of part of the intron. A three-nucleotide non-template sequence at the break point then allows an in-frame <italic>PPP1R10-FOSB</italic> fusion transcript to be produced. <bold>b</bold> Annotated schematic of the wild-type <italic>FOSB</italic> transcript with the published break points in the vascular tumours (pseudomyogenic haemangioendothelioma (PHE), epithelioid haemangioma (EH))</p></caption><graphic xlink:href="41467_2018_4530_Fig2_HTML" id="d29e707"/></fig></p><p id="Par9">Unusually for structural variants, all <italic>FOS</italic> break points were exonic, residing within a narrow genomic window of exon 4 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>). The rearrangements comprised both interchromosomal and intrachromosomal events. The rearrangement partners were introns of other genes (3/5 cases) or intergenic regions (2/5 cases). There was evidence of expression of the fusion transcript, visible as aberrant spikes in RNA-Seq read coverage adjacent to the break point in the fusion partners. However, these aberrantly transcribed sequences did not include any known exonic sequence. Indeed, stop codons were encountered at, or immediately after the break points (Fig.&#160;<xref rid="Fig1" ref-type="fig">1d</xref> and Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par10"><italic>FOSB</italic> rearrangements have been described in two different types of vascular tumours, namely pseudomyogenic haemangioendothelioma and epithelioid haemangioma<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. The interchromosomal translocation, found in PD7525a, occurred in the same region of exon 1 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). cDNA reads spanning the fusion junction support the expression of a fusion gene, connecting, in frame, <italic>PPP1R10</italic> to <italic>FOSB</italic>. Consequently, the expression of the <italic>FOSB</italic> fusion gene would be brought under the control of the <italic>PPP1R10</italic> promoter (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3</xref>).</p><p id="Par11">In contrast to the <italic>FOSB</italic> genomic alteration, the rearrangements of <italic>FOS</italic> do not involve coding sequence of other genes. Transcription remained under the control of its native promoter. Furthermore, in 2/5 cases the fusion partner did not lie within a gene. These observations are supported by re-analyses of RNA sequences of epithelioid haemangioma harbouring <italic>FOS</italic> rearrangements (Fig.&#160;<xref rid="Fig1" ref-type="fig">1d</xref>)<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Similarly to osteoblastoma, the break points in these vascular tumours clustered within the same narrow 200&#8201;bp window of exon 4. Furthermore, stop codons were again found in the immediate vicinity of the <italic>FOS</italic> break point.</p></sec><sec id="Sec5"><title><italic>FOS</italic> and <italic>FOSB</italic> alterations are ubiquitous in osteoblastoma</title><p id="Par12">To validate our findings, we examined by fluorescence in situ hybridisation (FISH) an extension cohort of 55 formalin-fixed paraffin-embedded (FFPE) histologically typical cases of osteoblastoma and osteoid osteoma (Supplementary Data&#160;<xref rid="MOESM4" ref-type="media">1</xref>). In these 55 samples, we found <italic>FOSB</italic> and <italic>FOS</italic> breakapart signals in 1 and 48 tumours, respectively (89% in total; Supplementary Data&#160;<xref rid="MOESM4" ref-type="media">1</xref>).</p><p id="Par13">We speculated that the six FISH-negative cases may also harbour <italic>FOS</italic> or <italic>FOSB</italic> rearrangements that were not detected because FISH analysis is hampered in tumours of low cellularity, a frequent feature of osteoblastoma<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. FISH may also miss cases with short distance intrachromosomal rearrangements, such as tandem duplications, that insufficiently separate probe target sequences. Since sufficient tissue was available for 3/6 negative cases, we sought alternative evidence for <italic>FOS</italic> dysregulation by immunohistochemistry. All three samples demonstrated strong nuclear FOS immunoreactivity, supporting the notion that alterations in <italic>FOS</italic> or <italic>FOSB</italic> underpin every case of osteoblastoma and osteoid osteoma (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4b</xref>). FOSB immunohistochemistry was uninformative in osteoblastoma, consistent with previous experience with decalcified tumours (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4c</xref>)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p></sec><sec id="Sec6"><title><italic>FOS</italic> and <italic>FOSB</italic> alterations are specific to benign bone tumours</title><p id="Par14">To explore the utility of our findings as diagnostic markers of osteoblastoma, we assessed their specificity across different tumour sets. We examined FOS immunoreactivity in 183 cases of osteosarcoma, including 97 cases of osteoblastic osteosarcoma, and 17 cases of angiosarcoma. In keeping with previous reports, FOS immunoreactivity was seen in osteosarcoma samples but only one had a distribution and intensity of immunoreactivity comparable with osteoblastoma<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. While there were no breakapart signals in <italic>FOS</italic> or <italic>FOSB</italic> on FISH testing, copy number gains were noted (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4d</xref>). We then examined 55 whole-genome sequences of two published osteosarcoma series, none of which harboured break points in <italic>FOS</italic> or <italic>FOSB</italic><sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Finally, we could not find similar <italic>FOS</italic> and <italic>FOSB</italic> rearrangements in whole-genome sequences in 2652 non-osteoblastoma tumours<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Taken together, our findings indicate that <italic>FOS</italic> and <italic>FOSB</italic> alterations may be exploited as diagnostic markers for osteoblastoma and osteoid osteoma. We also demonstrate for the first time that both tumour types are similar at a molecular level.</p></sec></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p id="Par15">Rearrangements of <italic>FOS</italic> moulded a mutant transcript that lacks regulatory elements. This configuration bears a striking resemblance to the retroviral oncogene, <italic>v-fos</italic>, identified in the FBJ murine osteosarcoma virus (Fig.&#160;<xref rid="Fig1" ref-type="fig">1c, d</xref>). Dysregulated expression of the murine orthologue, <italic>c-fos</italic>, can cause osteosarcoma in model systems but requires fusion with a highly active promoter and the <italic>v-fos</italic> 3&#8242; untranslated region<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par16">FOS levels are tightly regulated by both transcript and protein degradation. Two translation-dependent mechanisms ensure rapid mRNA degradation: a length-dependent interaction between the poly-A tail and an exon 3 domain (known as the major coding region determinant of instability)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, and an independent AU-rich element in the 3&#8242; untranslated region<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Both mechanisms are likely to be disrupted by the rearrangements we have found. Furthermore, ubiquitin-independent proteasomal degradation rapidly depletes the wild-type FOS protein<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The C-terminal truncations seen in epithelioid haemangioma have recently been shown to protect FOS from degradation<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. While the break points disrupt components of the C-terminal transactivation domain, this is not required for in vitro transformation by <italic>v-fos</italic><sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. While we cannot also exclude alteration of AP-1 activity we would expect increased FOS concentration in osteoblastoma cells. Consistent with this prediction, we observed intense nuclear immunoreactivity of FOS in osteoblastoma cells (Fig.&#160;<xref rid="Fig1" ref-type="fig">1f</xref> and Supplementary Data&#160;<xref rid="MOESM4" ref-type="media">1</xref>). Our findings may explain the absence of nonsense mutations in <italic>FOS</italic>, as only rearrangements could abolish both levels of regulation.</p><p id="Par17">Fifty years after the identification of <italic>v-fos</italic> we report human bone-forming tumours, osteoblastoma and osteoid osteoma, that are predominantly characterised by an aberrant <italic>FOS</italic> homologue resembling the viral <italic>fos</italic> oncogene. This shifts our understanding of <italic>FOS</italic>/AP-1 dysregulation in human bone tumours. Our findings also draw an intriguing parallel between bone-forming tumours and a subset of vascular tumours, suggesting possible shared developmental pathways. Patients are likely to benefit from our findings, as they can be readily translated into routine diagnostic practice.</p></sec><sec id="Sec8" sec-type="materials|methods"><title>Methods</title><sec id="Sec9"><title>Patient samples</title><p id="Par18">Patients provided their written and informed consent to provide samples for this study, which was approved by the National Research Ethics Service (NRES) Committee Yorkshire and The Humber &#8211; Leeds East (15/YH/0311).</p></sec><sec id="Sec10"><title>Sequencing</title><p id="Par19">Tumour DNA and RNA were derived from fresh-frozen tissue reviewed by bone pathologists (A.M.F./R.T./F.A.). Matched normal DNA was acquired from blood samples. Whole-genome sequencing was performed using the Illumina HiSeq 2000 or 2500 platform, using 100&#8201;bp paired-end sequencing. For whole-genome sequencing, we followed the Illumina no-PCR library protocol to construct short insert 500&#8201;bp libraries, prepare flowcells and generate clusters. The average coverage of tumours was at least 40&#215; and of normal DNA at least 30&#215; after alignment with BWA-Mem (2.0.54)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> (Supplementary Data&#160;<xref rid="MOESM12" ref-type="media">9</xref>). Poly-A RNA was sequenced on an Illumina HiSeq 2000 (75&#8201;bp paired-end). Sequenced RNA libraries were aligned with STAR (2.0.42)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p></sec><sec id="Sec11"><title>Variant detection</title><p id="Par20">The Cancer Genome Project (Wellcome Trust Sanger Institute) variant calling pipeline was used to call somatic mutations. The following algorithms, with standard settings, and no additional post-processing was used on aligned DNA BAM files: CaVEMan (1.11.0)<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> for substitutions; Pindel (2.1.0)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> for indels; BRASS (5.3.3 <ext-link ext-link-type="uri" xlink:href="https://github.com/cancerit/BRASS">https://github.com/cancerit/BRASS</ext-link>) for rearrangements, and ASCAT NGS (4.0.0)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> for copy number aberrations. Aligned RNA BAM files, including those realigned from published data, were run through the RNA-Seq analysis pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/cancerit/cgpRna/wiki">https://github.com/cancerit/cgpRna/wiki</ext-link>), which includes HTSeq (0.6.1)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> for gene feature counts, and the combination of STAR (2.5.0c), TopHat2 (2.1.0)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and deFuse (0.7.0)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> fusion discovery protocols.</p></sec><sec id="Sec12"><title>Variant validation</title><p id="Par21">The precision of Cancer Genome Project (Wellcome Trust Sanger Institute) variant calling pipeline has been determined in multiple studies<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. We confirmed this through manual inspection of raw sequencing reads. As for rearrangements, we only included break points in this data set that had been validated by reconstruction at base pair resolution.</p></sec><sec id="Sec13"><title>Analysis of mutations in cancer genes</title><p id="Par22">We analysed variants using a previously documented strategy<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In brief, we considered variants as potential drivers if they presented in established cancer genes (COSMIC v82). Tumour suppressor coding variants were considered if they were annotated as functionally deleterious by the in-house algorithm, VAGrENT (<ext-link ext-link-type="uri" xlink:href="http://cancerit.github.io/VAGrENT/">http://cancerit.github.io/VAGrENT/</ext-link>). Disruptive rearrangement break points in or homozygous deletions of tumour suppressors were also considered. Additionally, homozygous deletions were required to be focal (&lt;1&#8201;Mb in size). Mutations in oncogenes were considered driver events if they were located at previously reported hot spots (point mutations) or amplified the intact gene. Amplifications also had to be focal (&lt;1&#8201;Mb) result in at least five copies in diploid genomes.</p></sec><sec id="Sec14"><title>Fusion detection</title><p id="Par23">Rearrangements in <italic>FOS</italic> and <italic>FOSB</italic> were analysed using the DNA structural rearrangement caller, BRASS and the in-house RNA fusion detection algorithm, infuse. Fusions were considered if break points and orientations were supported by both algorithms. All reads supporting the break points were manually inspected. In sample PD13482, in which neither algorithm identified the fusion, both split reads and discordant read pairs spanning the fusion were identified in the DNA- and RNA-Seq data.</p><p id="Par24">All <italic>FOS</italic> fusion partner break points were located in genomic regions not normally represented in RNA sequencing libraries as they were intergenic or intronic segments. The per-base coverage in these regions therefore reveals a clear peak, present only in that tumour sample, demonstrating expression of aberrant transcripts (normalised by the mean of HTSeq counts &#215;10<sup>3</sup>). The end of the transcript was considered to be 10&#8211;30&#8201;bp downstream of the cleavage and poly-adenylation signal (&#8216;AATAAA&#8217;) with the greatest drop in coverage in the surrounding 200&#8201;bp. For schematic purposes, mean normalised coverage was plotted as a segment, as Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>: the &#8216;mate transcript segment&#8217; is between the break point (grey vertical dashed line) and the poly-adenylation cleavage site; surrounding segments are the mean sequencing coverage over a genomic range of equal length to the &#8216;mate transcript segment&#8217;.</p></sec><sec id="Sec15"><title>FOS fusion validation</title><p id="Par25">cDNA was synthesised from 1&#8201;&#181;g of total RNA was using the ProtoScript&#174; II First-Strand cDNA Synthesis Kit (NEB). PCR was performed with Phusion high-fidelity PCR master mix (HF buffer, NEB) using the primers listed in Supplementary Data&#160;<xref rid="MOESM13" ref-type="media">10</xref>. Amplified products were size selected using gel electrophoresis and then Sanger sequenced using an internal primer listed in Supplementary Data&#160;<xref rid="MOESM13" ref-type="media">10</xref>.</p></sec><sec id="Sec16"><title>Allele-specific expression analysis</title><p id="Par26">We analysed allele-specific expression in <italic>FOS</italic> and <italic>FOSB</italic> using allele counts at heterozygous single-nucleotide polymorphisms (SNPs). To allow for poor alignment in RNA-Seq data close to break points, allele counts at heterozygous SNPs were computed manually. Heterozygous SNPs were identified from DNA sequencing data. Allele counts were measured from RNA-Seq reads using GATK ASEReadCounter<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p></sec><sec id="Sec17"><title>Fluorescence in situ hybridisation (FISH) for <italic>FOS</italic> and <italic>FOSB</italic></title><p id="Par27">A cohort of 55 informative cases of osteoblastoma/osteoid osteoma was examined by FISH for <italic>FOS</italic> breakapart. <italic>FOSB</italic> probes were custom designed with Agilent SureDesign to flank the breakapart region. <italic>FOS</italic> probes and methods have been described previously<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> (Supplementary Data&#160;<xref rid="MOESM14" ref-type="media">11</xref>). In brief, deparaffinised sections were pretreated by pressure cooking for 5&#8201;min and subsequently incubated in pepsin solution at 37&#8201;&#176;C for 50&#8201;min. Probes were applied to tissue sections and denatured at 72&#8201;&#176;C, followed by hybridisation overnight at 37&#8201;&#176;C. After hybridisation, the sections were washed and mounted with 4&#8242;,6-diamidino-2-phenylindole and coverslips.</p></sec><sec id="Sec18"><title>Immunohistochemistry for FOS and FOSB</title><p id="Par28">Deparaffinised hydrated tissue sections underwent antigen unmasking in Tris-EDTA pH 9 (DAKO S2367 - Agilent Technologies LDA UK Limited, Cheshire, UK) at high pressure for 2&#8201;min. After washing and quenching, sections were blocked in 2.5% horse serum (Vector ImmPRESS Kit) for 20&#8201;min at room temperature. Incubation with primary antibodies was for 60&#8201;min, secondary antibodies for 30&#8201;min, and DAB&#8201;+&#8201;substrate/chromagen (Dako, K3468) for 5&#8201;min, all at room temperature, prior to counterstaining and mounting. FOS antibodies were EMD Millipore ABE457 (Rabbit Polyclonal, used at 1 or 0.5&#8201;&#181;g&#8201;mL<sup>&#8722;1</sup>) and ImmPRESS Horse Radish Peroxidase Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit, made in Horse (MP-7401, Vector Laboratories, Peterborough, UK) while FOSB antibodies (clone 5G4, dilution 1:100, Cell Signaling Technology, Danvers, MA and rabbit polyclonal CAMTA1 antibody Atlas Antibodies, Stockholm, Sweden) were as previously described<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p></sec><sec id="Sec19"><title>Data availability</title><p id="Par29">The authors declare that all data supporting the findings of this study are available within the article and its supplementary files or from the corresponding author on reasonable request. Sequencing data have been deposited at the European Genome-Phenome Archive (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/ega/">http://www.ebi.ac.uk/ega/</ext-link>) that is hosted by the European Bioinformatics Institute. DNA (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/datasets/EGAD00001000785">https://www.ebi.ac.uk/ega/datasets/EGAD00001000785</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/datasets/EGAD00001000147">https://www.ebi.ac.uk/ega/datasets/EGAD00001000147</ext-link>) accession numbers: EGAN00001100713, EGAN00001100730, EGAN00001100714, EGAN00001100731, EGAN00001100715, EGAN00001100732, EGAN00001031765, EGAN00001032117, EGAN00001031767, EGAN00001032119, EGAN00001036773, EGAN00001036983. RNA (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001000763">https://www.ebi.ac.uk/ega/studies/EGAS00001000763</ext-link>) accession numbers: EGAN00001196539, EGAN00001196540, EGAN00001209957, EGAN00001196544, EGAN00001196545, EGAN00001209959.</p></sec></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec21"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2018_4530_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2018_4530_MOESM2_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2018_4530_MOESM3_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2018_4530_MOESM4_ESM.xlsx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41467_2018_4530_MOESM5_ESM.xlsx"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41467_2018_4530_MOESM6_ESM.xlsx"><caption><p>Supplementary Data 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41467_2018_4530_MOESM7_ESM.xlsx"><caption><p>Supplementary Data 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41467_2018_4530_MOESM8_ESM.xlsx"><caption><p>Supplementary Data 5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41467_2018_4530_MOESM9_ESM.xlsx"><caption><p>Supplementary Data 6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="41467_2018_4530_MOESM10_ESM.xlsx"><caption><p>Supplementary Data 7</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="41467_2018_4530_MOESM11_ESM.xlsx"><caption><p>Supplementary Data 8</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="41467_2018_4530_MOESM12_ESM.xlsx"><caption><p>Supplementary Data 9</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM13"><media xlink:href="41467_2018_4530_MOESM13_ESM.xlsx"><caption><p>Supplementary Data 10</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM14"><media xlink:href="41467_2018_4530_MOESM14_ESM.xlsx"><caption><p>Supplementary Data 11</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>These authors contributed equally: Matthew W. Fittall, William Mifsud.</p></fn><fn><p>These authors jointly supervised this work: Adrienne M. Flanagan, Sam Behjati.</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p><bold>Supplementary Information</bold> accompanies this paper at 10.1038/s41467-018-04530-z.</p></fn><fn><p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was funded by The Wellcome Trust; Skeletal Cancer Action Trust UK; the Royal National Orthopaedic Hospital NHS Trust; Rosetrees Trust. A.M.F. is an NIHR senior investigator and was also supported by the National Institute for Health Research, UCLH Biomedical Research Centre and the UCL Experimental Cancer Centre. M.W.F., A.V., J.D., M.T. and P.V.L. are supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202) and the Wellcome Trust (FC001202). Personal fellowships have been granted to S.B. (Wellcome Trust Intermediate Clinical Research Fellowship; St. Baldrick&#8217;s Foundation Robert J. Arceci International Innovation Award); P.J.C. (Wellcome Trust Senior Clinical Research Fellowship); N.P. (CRUK Clinician Scientist Fellowship) and E.M. (CRUK Career Development Fellow); C.R.A. is supported by NIH grants (P50 CA140146-01 and P30 CA008748), M.W.F. (Crick-CRUK Doctoral Fellowship); J.D. (Research Foundation &#8211; Flanders, FWO Postdoctoral Fellowship; European Union&#8217;s Horizon 2020 Research and Innovation programme, MSCA 703594-DECODE); M.T. (European Union&#8217;s Horizon 2020 Research and Innovation programme postdoctoral fellowship, MSCA 747852-SIOMICS). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation&#8217;s support towards the establishment of The Francis Crick Institute. We are grateful to Donna Magsumbol for technical work, the RNOH Musculoskeletal Pathology Biobank biobank team for consenting patients and accessing samples and the UCL CRUK Cancer Centre Pathology Core Facility for immunohistochemistry. We thank patients for participating in our research and the clinical teams involved in their care.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>M.W.F. and W.M. performed data analyses. M.D.Y. and P.S.T. contributed to data analysis. C.R.A., L.Z., A.M.F., R.T., F.A. and W.M. contributed to design of FISH experiments and supplied BAC clones. H.Y., F.B. and A.-C.S. performed FISH analyses. E.M. and F.B. performed immunostaining. A.V. performed the fusion validation with PCR and Sanger sequencing. J.D. contributed to allele-specific expression analysis. A.M.F., W.M., R.T. and F.A. curated and reviewed the samples, clinical data and/or provided clinical expertise. M.T., N.P., J.D. and A.E.G. contributed to discussions. M.W.F., S.B. and A.V. contributed to figure design. A.M.F., P.V.L., S.B., M.R.S. and P.J.C. directed the research. M.W.F, S.B. and A.M.F. wrote the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Czerniak, B. &amp; Dorfman, H. D. <italic>Dorfman and Czerniak&#8217;s Bone Tumors</italic> (Elsevier, Philadelphia, 2016).</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nord</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e80725</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080725</pub-id><?supplied-pmid 24236197?><pub-id pub-id-type="pmid">24236197</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannico</surname><given-names>G</given-names></name><etal/></person-group><article-title>Osteoblastoma characterized by a three-way translocation: report of a case and review of the literature</article-title><source>Cancer Genet. Cytogenet.</source><year>2009</year><volume>195</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2009.06.024</pub-id><?supplied-pmid 19963118?><pub-id pub-id-type="pmid">19963118</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>AE</given-names></name></person-group><article-title>Bone-forming tumors</article-title><source>Surg. Pathol. Clin.</source><year>2017</year><volume>10</volume><fpage>513</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.path.2017.04.006</pub-id><?supplied-pmid 28797500?><pub-id pub-id-type="pmid">28797500</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>C</given-names></name><etal/></person-group><article-title>A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma</article-title><source>J. Pathol.</source><year>2014</year><volume>232</volume><fpage>534</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1002/path.4322</pub-id><?supplied-pmid 24374978?><pub-id pub-id-type="pmid">24374978</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonescu</surname><given-names>CR</given-names></name><etal/></person-group><article-title>ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features</article-title><source>Genes Chromosomes Cancer</source><year>2014</year><volume>53</volume><fpage>951</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1002/gcc.22206</pub-id><?supplied-pmid 25043949?><pub-id pub-id-type="pmid">25043949</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van IJzendoorn</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Fusion events lead to truncation of FOS in epithelioid hemangioma of bone</article-title><source>Genes Chromosomes Cancer</source><year>2015</year><volume>54</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1002/gcc.22269</pub-id><?supplied-pmid 26173738?><pub-id pub-id-type="pmid">26173738</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal</article-title><source>Am. J. Surg. Pathol.</source><year>2015</year><volume>39</volume><fpage>1313</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000469</pub-id><?supplied-pmid 26135557?><pub-id pub-id-type="pmid">26135557</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>YP</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name></person-group><article-title>FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma</article-title><source>Am. J. Surg. Pathol.</source><year>2017</year><volume>41</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000795</pub-id><?supplied-pmid 28009608?><pub-id pub-id-type="pmid">28009608</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weekes</surname><given-names>D</given-names></name><etal/></person-group><article-title>Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>2948</fpage><pub-id pub-id-type="doi">10.1038/onc.2015.420</pub-id><?supplied-pmid 27251742?><pub-id pub-id-type="pmid">27251742</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KS</given-names></name><etal/></person-group><article-title>A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma</article-title><source>Cold Spring Harb. Mol. Case Stud.</source><year>2016</year><volume>2</volume><fpage>a000992</fpage><pub-id pub-id-type="doi">10.1101/mcs.a000992</pub-id><?supplied-pmid 27626065?><pub-id pub-id-type="pmid">27626065</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behjati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15936</fpage><pub-id pub-id-type="doi">10.1038/ncomms15936</pub-id><?supplied-pmid 28643781?><pub-id pub-id-type="pmid">28643781</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Li, Y. et al. Patterns of structural variation in human cancer. Preprint at <italic>bioRxiv</italic><ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/early/2017/08/27/181339">https://www.biorxiv.org/content/early/2017/08/27/181339</ext-link> (2017).</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigoriadis</surname><given-names>AE</given-names></name><name><surname>Schellander</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name></person-group><article-title>Osteoblasts are target cells for transformation in c-fos transgenic mice</article-title><source>J. Cell Biol.</source><year>1993</year><volume>122</volume><fpage>685</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1083/jcb.122.3.685</pub-id><?supplied-pmid 8335693?><pub-id pub-id-type="pmid">8335693</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosset</surname><given-names>C</given-names></name><etal/></person-group><article-title>A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00102-1</pub-id><?supplied-pmid 11051545?><pub-id pub-id-type="pmid">11051545</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>TM</given-names></name><name><surname>Shyu</surname><given-names>AB</given-names></name></person-group><article-title>Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function</article-title><source>Mol. Cell. Biol.</source><year>1994</year><volume>14</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1128/MCB.14.1.416</pub-id><?supplied-pmid 7903419?><pub-id pub-id-type="pmid">7903419</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>P</given-names></name><etal/></person-group><article-title>The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>1461</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206266</pub-id><?supplied-pmid 12629509?><pub-id pub-id-type="pmid">12629509</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">van Ijzendoorn, D. G. P. et al. Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. <italic>J. Biol. Chem</italic>. <bold>292</bold>, 21282&#8211;21290 (2017).</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jooss</surname><given-names>KU</given-names></name><name><surname>Funk</surname><given-names>M</given-names></name><name><surname>M&#252;ller</surname><given-names>R</given-names></name></person-group><article-title>An autonomous N-terminal transactivation domain in Fos protein plays a crucial role in transformation</article-title><source>EMBO J.</source><year>1994</year><volume>13</volume><fpage>1467</fpage><lpage>1475</lpage><?supplied-pmid 8137828?><pub-id pub-id-type="pmid">8137828</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>JA</given-names></name><name><surname>Cook</surname><given-names>A</given-names></name><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>Conserved motifs in Fos and Jun define a new class of activation domain</article-title><source>Genes Dev.</source><year>1992</year><volume>6</volume><fpage>1810</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1101/gad.6.9.1810</pub-id><?supplied-pmid 1516835?><pub-id pub-id-type="pmid">1516835</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Li, H. &amp; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. <italic>Bioinformatics</italic><bold>25</bold>, 1754&#8211;1760 (2009).</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Dobin, A et al. STAR: ultrafast universal RNA-seq aligner. <italic>Bioinformatics</italic><bold>29</bold>, 15&#8211;21 (2013).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data. <italic>Curr. Protoc. Bioinformatics</italic><bold>56</bold>, 15.10.1&#8211;15.10.18 (2016).</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Schulz</surname><given-names>MH</given-names></name><name><surname>Long</surname><given-names>Q</given-names></name><name><surname>Apweiler</surname><given-names>R</given-names></name><name><surname>Ning</surname><given-names>Z</given-names></name></person-group><article-title>Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>2865</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp394</pub-id><?supplied-pmid 19561018?><pub-id pub-id-type="pmid">19561018</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Loo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Allele-specific copy number analysis of tumors</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16910</fpage><lpage>16915</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009843107</pub-id><?supplied-pmid 20837533?><pub-id pub-id-type="pmid">20837533</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><?supplied-pmid 25260700?><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. <italic>Genome Biol</italic>. <bold>14</bold>, R36 (2013).</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>A</given-names></name><etal/></person-group><article-title>deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data</article-title><source>PLoS Comput. Biol.</source><year>2011</year><volume>7</volume><fpage>e1001138</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1001138</pub-id><?supplied-pmid 21625565?><pub-id pub-id-type="pmid">21625565</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature17676</pub-id><?supplied-pmid 27135926?><pub-id pub-id-type="pmid">27135926</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Res.</source><year>2010</year><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><?supplied-pmid 20644199?><pub-id pub-id-type="pmid">20644199</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics</article-title><source>Diagn. Pathol.</source><year>2016</year><volume>11</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13000-016-0530-2</pub-id><?supplied-pmid 27515856?><pub-id pub-id-type="pmid">27515856</pub-id></element-citation></ref></ref-list></back></article>